Gelteq Business Summary

Gelteq Ltd (GELS) operates as a clinical and science-based drug delivery company specializing in the development and commercialization of a patented, gel-based oral delivery system. The company generates revenue through a multi-pronged model involving white-label manufacturing, product licensing, and end-to-end formulation services for third-party partners. Its operations are diversified across five core business segments: pharmaceuticals (prescription and OTC), nutraceuticals, sports performance, animal health (veterinary and pet care), and medicinal cannabinoids. By leveraging its proprietary technology to enhance the bioavailability of oil-soluble and poorly soluble drugs, Gelteq positions itself as a specialty solution provider for patients with dysphagia or those requiring precise, non-invasive dosing. Within the specialty drug delivery market, Gelteq competes with firms such as Dyadic International (DYAI), Kyntra Bio (KYNB), and Aytu BioPharma (AYTU), distinguishing itself through its unique focus on edible gel matrices rather than traditional lipid-based or injectable alternatives. The company was co-founded by CEO Nathan Givoni and Director Simon Szewach, both of whom bring extensive experience in health sciences and commercial technology. Givoni, a clinical dietitian and exercise physiologist, oversees the company’s scientific and operational strategy, while Szewach provides a background in scaling technology startups and consumer engagement. The technical leadership is further strengthened by Chief Scientific Officer Dr. Paul Wynne, who joined in late 2024 with over 35 years of experience in pharmaceutical formulation and analytical chemistry, and CFO Thuy-Linh Gigler, appointed in June 2025 to manage the firm’s financial expansion. Gelteq’s growth is supported by strategic institutional backing, notably a $12 million funding commitment from Lincoln Park Capital, LLC, and its board includes prominent figures such as the Hon. Philip Dalidakis and Jeffrey W. Olyniec of Moneta Ventures, reflecting a strong governance structure aimed at global commercialization.